Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Teerlink

Showing results (31-40 of 128) with videos related to

Pageof 13
Sort By:
Fertility and Sterility|December 14, 2004
HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal womenTatjana E Vogelvang, Velja Mijatovic, Peter Kenemans, et al.
Atherosclerosis|November 7, 2006
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized studyMarieke O Verhoeven, Majoie Hemelaar, Tom Teerlink, et al.
Plos One|May 21, 2014
Resting brain perfusion and selected vascular risk factors in healthy elderly subjectsOtto M Henriksen, Lars T Jensen, Katja Krabbe, et al.
The Journal of Nutrition|October 7, 2004
Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure?Robert J Nijveldt, Michiel P C Siroen, Tom Teerlink, et al.
Clinical Chemistry and Laboratory Medicine|April 8, 2006
Quantitative determination of erythrocyte folate vitamer distribution by liquid chromatography-tandem mass spectrometryDesirée E C Smith, Robert M Kok, Tom Teerlink, et al.
Menopause (New York, N.Y.)|December 6, 2006
Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal womenMarieke O Verhoeven, Tom Teerlink, Peter Kenemans, et al.
Nutrients|March 29, 2018
Folinic Acid Increases Protein Arginine Methylation in Human Endothelial CellsRuben Esse, Tom Teerlink, Pieter Koolwijk, et al.
Diabetes/Metabolism Research and Reviews|July 13, 2006
Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular diseaseRoger K Schindhelm, Michaela Diamant, Jacqueline M Dekker, et al.
American Journal of Hematology|April 3, 2008
Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisisPrecious P Landburg, Tom Teerlink, Frits A J Muskiet, et al.
Annals of the New York Academy of Sciences|December 15, 2007
Methylglyoxal and methylglyoxal-arginine adducts do not directly inhibit endothelial nitric oxide synthaseOlaf Brouwers, Tom Teerlink, Jan van Bezu, et al.
Pageof 13

Showing results (31-40 of 128) with videos related to

Sort By:
Pageof 13
Fertility and Sterility|December 14, 2004
HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal womenTatjana E Vogelvang, Velja Mijatovic, Peter Kenemans, et al.
Atherosclerosis|November 7, 2006
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized studyMarieke O Verhoeven, Majoie Hemelaar, Tom Teerlink, et al.
Plos One|May 21, 2014
Resting brain perfusion and selected vascular risk factors in healthy elderly subjectsOtto M Henriksen, Lars T Jensen, Katja Krabbe, et al.
The Journal of Nutrition|October 7, 2004
Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure?Robert J Nijveldt, Michiel P C Siroen, Tom Teerlink, et al.
Clinical Chemistry and Laboratory Medicine|April 8, 2006
Quantitative determination of erythrocyte folate vitamer distribution by liquid chromatography-tandem mass spectrometryDesirée E C Smith, Robert M Kok, Tom Teerlink, et al.
Menopause (New York, N.Y.)|December 6, 2006
Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal womenMarieke O Verhoeven, Tom Teerlink, Peter Kenemans, et al.
Nutrients|March 29, 2018
Folinic Acid Increases Protein Arginine Methylation in Human Endothelial CellsRuben Esse, Tom Teerlink, Pieter Koolwijk, et al.
Diabetes/Metabolism Research and Reviews|July 13, 2006
Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular diseaseRoger K Schindhelm, Michaela Diamant, Jacqueline M Dekker, et al.
American Journal of Hematology|April 3, 2008
Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisisPrecious P Landburg, Tom Teerlink, Frits A J Muskiet, et al.
Annals of the New York Academy of Sciences|December 15, 2007
Methylglyoxal and methylglyoxal-arginine adducts do not directly inhibit endothelial nitric oxide synthaseOlaf Brouwers, Tom Teerlink, Jan van Bezu, et al.
Pageof 13